Senate Files

Bills

S. 476 118th Congress

Maintaining Investments in New Innovation Act

Latest action, Feb 16, 2023: Read twice and referred to the Committee on Finance.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

3 cosponsors

Sponsored by Robert Menendez (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
0 D · 3 R
  • Democrat
  • Republican
  • Independent
3 senators cosponsoring

Referred to: Senate: Finance Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

25 clientsQ1 2023Q4 2024

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ALNYLAM PHARMACEUTICALS, INC.
TIBER CREEK GROUP
8 reports
ALNYLAM PHARMACEUTICALS, INC.
SPLITOAK STRATEGIES LLC
8 reports
INTERNATIONAL BROTHERHOOD OF TEAMSTERS
8 reports
NOVARTIS
8 reports
NOVARTIS
TIBER CREEK HEALTH STRATEGIES, INC.
8 reports
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
TIBER CREEK GROUP
8 reports
ALNYLAM PHARMACEUTICALS
THE MCMANUS GROUP
7 reports
NOVARTIS
BROWNSTEIN HYATT FARBER SCHRECK, LLP
7 reports
GENENTECH
THE MCMANUS GROUP
5 reports
MERCK & CO INC
5 reports
NOVARTIS
RESOLUTION PUBLIC AFFAIRS, LLC
5 reports
NOVARTIS, INC.
FORBES-TATE
5 reports
NOVARTIS, INC.
TODD STRATEGY GROUP
5 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
4 reports
ALEXION PHARMACEUTICALS, INC.
TODD STRATEGY GROUP
3 reports
All 25 of 33 clients
ClientLobbying firmReportsReports totalingFromToSenate
ALNYLAM PHARMACEUTICALS, INC.TIBER CREEK GROUP8$100KQ1 2023Q3 2024yes
ALNYLAM PHARMACEUTICALS, INC.SPLITOAK STRATEGIES LLC8$100KQ1 2023Q3 2024yes
INTERNATIONAL BROTHERHOOD OF TEAMSTERS8$2.3MQ1 2023Q3 2024yes
NOVARTIS8$11.7MQ1 2023Q3 2024yes
NOVARTISTIBER CREEK HEALTH STRATEGIES, INC.8$0Q1 2023Q3 2024yes
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)TIBER CREEK GROUP8$480KQ1 2023Q3 2024yes
ALNYLAM PHARMACEUTICALSTHE MCMANUS GROUP7$50KQ4 2023Q3 2024yes
NOVARTISBROWNSTEIN HYATT FARBER SCHRECK, LLP7$0Q4 2023Q3 2024yes
GENENTECHTHE MCMANUS GROUP5$0Q4 2023Q3 2024yes
MERCK & CO INC5$12.2MQ1 2023Q1 2024yes
NOVARTISRESOLUTION PUBLIC AFFAIRS, LLC5$0Q4 2023Q3 2024yes
NOVARTIS, INC.FORBES-TATE5$0Q4 2023Q3 2024yes
NOVARTIS, INC.TODD STRATEGY GROUP5$0Q2 2023Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATION4$7.5MQ4 2023Q3 2024yes
ALEXION PHARMACEUTICALS, INC.TODD STRATEGY GROUP3$240KQ4 2024Q3 2024yes
ALNYLAM PHARMACEUTICALS, INC.TODD STRATEGY GROUP3$0Q4 2024Q3 2024yes
GILEAD SCIENCES, INC.THE MCMANUS GROUP3$0Q4 2024Q3 2024yes
GSK (FKA GLAXOSMITHKLINE INC.)3$3.4MQ4 2023Q3 2023yes
NOVARTISTARPLIN, DOWNS & YOUNG, LLC3$0Q4 2024Q3 2024yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA3$19.1MQ4 2023Q3 2023yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATHE MCMANUS GROUP3$0Q4 2024Q3 2024yes
AARP2$10.0MQ2 2024Q3 2024yes
ALNYLAM PHARMACEUTICALS, INC.2$440KQ4 2023Q3 2023yes
IONIS PHARMACEUTICAL, INC.FORBES-TATE2$60KQ4 2024Q3 2024yes
IONIS PHARMACEUTICALS, INC.2$160KQ4 2024Q3 2024yes